RTP Mobile Logo
Proceedings from the 15th Annual Winter Lung Cancer Conference
Released April 2018

Proceedings from a live event featuring traditional didactic faculty presentations and case-based panel discussions focused on all factors that influence multidisciplinary treatment decision-making for lung cancer. Featuring perspectives from Ethan M Basch, Jeffrey Crawford, Jesse R Fann, Leena Gandhi, Edward B Garon, Matthew Gubens, Nasser H Hanna, Jennifer M Kapo, Rogerio C Lilenbaum, Billy W Loo Jr, Naiyer Rizvi, Lecia V Sequist, Mark A Socinski, Anne S Tsao and Douglas E Wood. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows and other allied cancer professionals involved in the treatment of lung cancer.

    OVERVIEW OF ACTIVITY
    Lung cancer is a devastating disease with broad-reaching impact on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In the year 2018, it is estimated that more than 234,030 individuals will be diagnosed and more than 154,050 will die from the disease. Importantly, despite the many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, however, this field is seeing renewed optimism that these trends have already started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine. Over the past several years major clinical trials in lung cancer have witnessed a host of promising successes, many of which are already being operationalized in clinical practice. Even so, these achievements will doubtlessly continue to be dissected in the upcoming years and will further challenge the collective understanding of the biology and optimal management of this disease. Several consensus- and evidence-based treatment guidelines are currently available and aim to assist clinicians with making lung cancer treatment decisions in the face of this dynamic clinical environment, but despite the existence of these tools, many areas of controversy persist within academic and community settings.

    These video proceedings from a live CME symposium feature the perspectives of a multidisciplinary panel of clinical investigators on key challenges and controversies in the treatment of lung cancer. By providing information on the latest research developments and their potential application to routine practice, this activity will assist medical oncologists, hematology-oncology fellows and other allied cancer professionals in staying up to date in a continuously evolving therapeutic environment.

    LEARNING OBJECTIVES

    • Design evidence-based strategies for the diagnosis and management of Stage I to Stage III non-small cell lung cancer (NSCLC), considering the potential contributions of systemic and/or local therapeutic modalities.
    • Appreciate the FDA approval of durvalumab and available Phase III data documenting the benefit of sequential anti-PD-L1 therapy after the completion of chemoradiation therapy for Stage III NSCLC, and consider the role of this therapeutic approach for appropriate patients.
    • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, select optimal testing platforms and appropriately apply the results to individualize first- and later-line therapy for patients with NSCLC according to their potential response or resistance to a specific treatment.
    • Review published research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
    • Consider age, performance status, PD-L1 tumor proportion score and other patient or disease characteristics to guide the selection of induction and maintenance systemic therapy for patients with metastatic NSCLC without an identifiable driver mutation.
    • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC.
    • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
    • Assess other oncogenic pathways mediating the growth of tumors in unique subsets, and recall emerging data with commercially available and experimental agents exploiting these targets.
    • Describe ongoing trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, anti-PD-1/PD-L1 antibodies in combination with other checkpoint inhibitors, chemotherapy or targeted therapy) for diverse lung cancer variants, and counsel appropriately selected patients about participation.
    • Formulate management strategies for small cell lung cancer, considering the contributory roles of local and systemic therapy in addition to current research studies evaluating novel immunotherapeutic and targeted approaches.
    • Consider the use of multimodality therapy for appropriate patients with mesothelioma who might be cured with this approach, and devise optimal management strategies for those with advanced disease, including the option of clinical trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 11.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/WLCC2018/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ethan M Basch, MD, MSc
    Professor of Medicine and Public Health
    Director, Cancer Outcomes Research Program
    Co-Leader, Cancer Prevention and Control
    Associate Chief, Division of Oncology
    University of North Carolina
    Chapel Hill, North Carolina

    No relevant conflicts of interest to disclose.

    Jeffrey Crawford, MD
    George Barth Geller Professor for Research in Cancer
    Co-Director, Solid Tumor Therapeutics Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Merck, Pfizer Inc; Data and Safety Monitoring Board: BeyondSpring Pharmaceuticals, Celgene Corporation, G1 Therapeutics, Genentech BioOncology, Janssen Biotech Inc, Merrimack Pharmaceuticals Inc, Mylan Pharmaceuticals Inc, Roche Laboratories Inc.

    Jesse R Fann, MD, MPH
    Director, Psychiatry and Psychology Service
    Seattle Cancer Care Alliance
    Clinical Research Division
    Fred Hutchinson Cancer Research Center
    Professor, Department of Psychiatry and Behavioral Sciences
    University of Washington
    Seattle, Washington

    Consulting Agreements: Quartet Health; Stock Ownership: Pfizer Inc.

    Leena Gandhi, MD, PhD
    Director, Perlmutter Cancer Center
    Langone Health
    New York University
    New York, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Ignyta Inc, Merck, Syndax Pharmaceuticals Inc.

    Edward B Garon, MD, MS
    Associate Professor
    Director, Thoracic Oncology Program
    Jonsson Comprehensive Cancer Center
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Merck, Mirati Therapeutics, Novartis, Pfizer Inc.

    Matthew Gubens, MD, MS
    Associate Professor, Thoracic Medical Oncology
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Mersana Therapeutics, Novartis; Contracted Research: Celgene Corporation, Merck, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    Nasser H Hanna, MD
    Associate Professor of Medicine
    Indiana University
    Indianapolis, Indiana

    Contracted Research: Bristol-Myers Squibb Company, Merck.

    Jennifer M Kapo, MD
    Associate Professor of Medicine (Geriatrics)
    Chief, Palliative Medicine
    Smilow Cancer Hospital
    Yale Cancer Center
    New Haven, Connecticut

    No relevant conflicts of interest to disclose.

    Rogerio C Lilenbaum, MD (Co-Chair and Moderator)
    Professor of Medicine
    Yale School of Medicine
    Chief Medical Officer
    Smilow Cancer Hospital
    Yale Cancer Center
    New Haven, Connecticut

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology; Consulting Agreement: Roche Laboratories Inc; Contracted Research: Celgene Corporation.

    Billy W Loo Jr, MD, PhD, DABR
    Associate Professor, Thoracic Radiation Oncology Program Leader
    New Technologies Committee Co-Chair
    Department of Radiation Oncology
    Stanford Cancer Institute
    Stanford, California

    Board Member and Ownership Interest: TibaRay Inc.

    Gregory J Riely, MD, PhD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Contracted Research: Genentech BioOncology, Pfizer Inc, Takeda Oncology; Paid Travel: Merck; Other: AstraZeneca Pharmaceuticals LP.

    Naiyer Rizvi, MD
    Professor of Medicine
    Director of Thoracic Oncology and Phase I Immunotherapeutics
    Price Chair in Clinical Translational Research
    Columbia University Medical Center
    New York, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc.

    Lecia V Sequist, MD, MPH
    Associate Professor of Medicine
    Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Novartis.

    Mark A Socinski, MD (Co-Chair and Moderator)
    Executive Medical Director
    Member, Thoracic Oncology Program
    Florida Hospital Cancer Institute
    Orlando, Florida

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Takeda Oncology.

    Anne S Tsao, MD
    Professor
    Director, Mesothelioma Program
    Director, Thoracic Chemo-Radiation Program
    The University of Texas MD Anderson Cancer Center
    Department of Thoracic/Head and Neck Medical Oncology
    Houston, Texas

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Lilly, Merck, Novartis, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Merck.

    Douglas E Wood, MD
    The Henry N Harkins Professor and Chair
    Department of Surgery
    University of Washington
    Seattle, Washington

    No relevant conflicts of interest to disclose.

    MODERATOR AND CO-CHAIR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Lilly, Novartis and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2018
    Expiration date: April 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Keynote

Management of Non-Small Cell Lung Cancer (NSCLC) with a Targetable Mutation — Part 1

Management of NSCLC with a Targetable Mutation — Part 2

Current and Future Application of Immunotherapy in Lung Cancer — Part 1: NSCLC

Current and Future Application of Immunotherapy in Lung Cancer — Part 2: Small Cell Lung Cancer (SCLC) and Malignant Pleural Mesothelioma (MPM)

Meet the Professors: Palliative Care and Psychiatric Support for Patients with NSCLC

Surgery, Radiation Therapy and Other Issues in the Management of NSCLC

Practical Clinical Issues in the Treatment of Locally Advanced NSCLC in the Current Era

Select Publications